Objectives: Vulva cancer (VC) treatment carries a high risk of severe late effects that may have a negative impact on quality of life (QoL). Patient-reported outcome measures (PROMs) are increasingly used when evaluating disease-and treatment-specific effects. However, the adequacy of measures used to assess sequelae and QoL in VC remains unclear. The aims of the present study were to evaluate disease-and treatment-related effects as measured by PROMs in VC patients and to identify available VC-specific PROMs. Methods/Materials: A systematic literature search from 1990 to 2016 was performed. The inclusion criterion was report of disease-and treatment-related effects in VC patients using PROMs in the assessment. Methodological and reporting quality was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. This systematic review was performed as part of phase 1 of the development of a European Organisation for Research and Treatment of Cancer QoL questionnaire for VC patients. Results: The search revealed 2299 relevant hits, with 11 articles extracted including a total of 535 women with VC; no randomized controlled trials were identified. The selected studies exhibited great heterogeneity in terms of PROMs use. Twenty-one different instruments assessed QoL. Most of the questionnaires were generic. Different issues (sexuality, lymphedema, body image, urinary and bowel function, vulva-specific symptoms) were reported as potentially important, but the results were not systematically collected. Only one VC-specific questionnaire was identified but did not allow for assessment and reporting on a scale level. Conclusions: Vulva cancer treatment is associated with considerable morbidity deteriorating QoL. To date, there is no validated PROM available that provides adequate coverage of VC-related issues. The study confirms the need for a VC-specific QoL instrument with REVIEW ARTICLE
T he surgical treatment of vulvar cancer (VC) has changed dramatically in the last few decades toward a less radical approach. The standard treatment of small tumors (G4 cm) is wide local excision (WLE) combined with sentinel lymph node biopsy (SLNB) and vulvectomy with inguinal lymph node dissection (ILND) for larger tumors or sentinel node metastases. 1Y3 In the case of metastatic lymph nodes in the groin, adjuvant radiation therapy (RT) improves survival. 4 Primary or neoadjuvant chemoradiation (CRT) is considered in locally advanced unresectable tumors involving the urethra or anus. 5Y7 Despite the less radical surgery to the vulva and groin, multimodality treatment is mutilating and associated with a high risk of short-and long-term consequences that may interfere with the quality of life (QoL). 8Y14 Several aspects of treatment options are being investigated and issues related to radicality of surgery and radiotherapy are still unresolved. The patient perspective is important when evaluating treatment effects. Patient-reported outcome measures (PROMs) complements clinical data with the patient's perspective, and there is an increasing demand for systematic implementation of PROMs in daily clinical practice and clinical trials. 15 It has therefore become important to develop PROMs that allow for broad cross-cultural application.
The aims of the present study were to evaluate disease-and treatment-related effects as measured by PROMs in VC patients and to identify available VC-specific PROMs, with the overall purpose of assessing the need for developing a new questionnaire module that specifically focuses on the consequences of VC treatment. This systematic review was performed as part of the first of 4 phases in the development of a new questionnaire module for QoL assessment in VC patients, alongside the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30). 16 
MATERIALS AND METHODS
The present systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 17 The population included women undergoing surgery and/or CRT for primary or recurrent VC. The primary outcome was VC-specific PROMs, which were not covered by generic questionnaires. Furthermore, studies were excluded if they included fewer than 20 patients or involved patients with vulvar intraepithelial lesions or nonvulvar gynecological cancer patients only, unless results for a VC subgroup were reported separately. We also excluded studies evaluating late effects after ''en bloc'' vulvectomy because this procedure has been replaced by individualized surgery. Finally, articles reporting on acute or late effects as rated by health care professionals, surgical guidelines, case reports, letters to the editor, or reviews were excluded.
Literature Search
The search was conducted by one author (L.P.F.) in collaboration with an information specialist at Copenhagen University Library. The PubMed, Embase, the Cochrane Library, CINAHL, and psychINFO were searched for articles reported in English and published since 1990 using the following search string:
(''Vulvar Neoplasms'') OR ((Vulva*) AND (Neoplasm* OR Cancer* OR Tumor* OR Tumour* OR Malign* OR Carcinom*)) AND ((''Sexual Dysfunction]) OR (''Quality of Life'') OR ''Complications'' OR ''Morbidity'' OR ''Lymphedema'' OR ''Body Image OR ''Proctitis'' OR ''Urology'' OR ''Groin'')). In PubMed, all search terms were coined as MESH terms and as title/abstract, ensuring the capture of articles that had not yet been indexed. No constraints related to publication type were applied. The primary search was performed on April 1, 2011, as the initial step in developing an EORTC QoL questionnaire for VC. The search was updated on February 5, 2016 , for the present systematic review.
Study Selection and Data Collection
The titles of all studies were reviewed by 2 authors (L.P.F., P.T.J.). If both authors agreed, studies were included/ excluded. Disagreements were resolved by consensus. Reference lists of identified articles were reviewed. Subsequently, all potentially included articles were further screened by abstract by both authors. The study selection process is shown in Figure 1 .
RESULTS

Literature Search and Study Selection
Eleven original studies were selected through a stepwise exclusion (Fig. 1 ) from the 2299 studies initially identified in the search. No randomized controlled trials were identified. The characteristics of the included studies are shown in Table 1 . The studies comprised 535 cases of VC. The patients' age ranged from 24 to 98 years. Four of the studies included patients who had recurrent disease. In general, all studies were small, with fewer than 100 patients included. The methodological quality of the studies is summarized in Table 2 .
Questionnaires Used
In the included studies, 21 different questionnaires were used to assess QoL (Table 2) . Seven studies used cancer-specific generic questionnaires: EORTC QLQ-C30, The Functional Assessment of Cancer TherapyVGeneral, and the Utility-Based Questionnaire Cancer.
29Y31 One nonYcancer-specific generic QoL instrument, the Medical Outcomes Study Short-Form SF Health Survey (36-item and 12-item), was used in 3 studies (Table 2) . 32 All of the included generic questionnaires have been validated and used in different patient populations and will not be further commented upon.
In 7 of the studies, nonYvulva-specific questionnaires were used to assess disease-and treatment-related outcomes in VC patients: the EORTC QLQ Cervical Cancer Module (CX24), the Female Sexual Function Index (FSFI), the Electronic Pelvic Floor Assessment Questionnaire (ePAQ-PF), the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and the Body Image Scale (BIS; Table 3 ).
33Y37 One VC-specific QoL questionnaire was identified. 19 The Functional Assessment of Cancer Therapy Vulva (FACT-V) consists of 15 single items assessing different aspects of patients' concerns. 38 
VC-specific Effects and QoL Issues Vulva-specific Symptoms
Vulva-specific symptoms were assessed in 2 studies 19, 20 using the FACT-V (Tables 2 and 3 ). In the study by Oonk et al, 20 no differences in vulva-specific symptoms (discharge/blood loss, odor, itching, and pain/numbness) were identified between patients treated with SLNB compared with those treated with ILND. Most patients (94%) included in this study received WLE. They reported on subscale level for the vulva symptoms, 20 although no scale structure was given in the article on validation of the FACT-V. 19 In the study by Janda et al, 19 patients treated for recurrent disease (8/97 patients) had a significantly lower FACT-V summary score (P = 0.03), indicating a worse QoL and a higher level of symptoms compared with patients with primary disease. However, all symptoms were summarized in 1 scale score. 19 When assessing patients longitudinally (20 patients) within the same study, symptoms related to the vulva (discharge/bleeding, odor, itching/burning) improved at 2 months after surgery as compared with baseline. 19 
Sexual Function
Different aspects of sexual function (SXF) were evaluated in all the included studies by self-designed nonvalidated questionnaires, 18 ,23Y25 the FSFI, 21,22,27 the SXF scale, or sexual single items of the EORTC QLQ-CX24 and the general sex life domain of the ePAQ-PF 26, 28 (Tables 2 and 3 ). Two studies used the FACT-V questionnaire (Tables 2 and 3 ), but for 15 items of very different issues, only summary scores were given; no scores on SXF or vaginal problems were presented. 19, 20 Information on sexual activity (yes or no) was given in 8 studies and varied between 8% and 61%, with baseline data available in 3 studies. 18,20Y26 Only half of the sexually active women regained sexual activity within 6 months after surgery. 18 , 23 Gunther et al 24 found decreased sexual activity in women treated with vulvectomy compared with women treated with WLE (16% vs 43%), whereas 3 other studies assessing changes in sexual activity over time and across surgical methods were not able to detect differences regardless of the questionnaire used (FACT-V, FSFI, EORTC QLQ-CX24; Tables 2 and 3) . 20, 21, 26 Two studies identified significantly decreased desire and arousal, 18 and more problems with dyspareunia and ability to achieve orgasm in VC patients compared with healthy control women 23 using selfdesigned nonvalidated questionnaires (Table 2 ). Significant deterioration of general SXF over time before and after the treatment in VC patients was reported in 2 studies, assessed by self-designed nonvalidated questionnaire and the general sex life domain of the ePAQ-PF (Tables 2 and 3) . 18, 39 Furthermore, in one study, adjuvant inguinal RT was negatively associated with the ability to achieve orgasm (P = 0.01). 21 Factors associated with posttreatment sexual dysfunction included ILND, 27 older age 18, 21, 22, 27 poor performance status, a history of depression, and preoperative psychosexual difficulties. 18 
Body Image
Body image (BI) was assessed in 5 studies 18Y21,26 by 4 questionnaires (FACT-V, EORTC QLQ-CX24, BIS, and a self-designed questionnaire; Tables 2 and 3 ). In the study by Green et al, 18 women after vulvectomy were questioned on BI disturbances before surgery and 3 months after treatment using a self-designed questionnaire (5 items on BI). A significant worsening in BI after surgery compared with baseline was reported (P = 0.004). 18 In the study by Novackova et al, 26 women had a significantly worse BI after vulvectomy and ILND as compared with women who had WLE and SLNB (P = 0.033) at 12-month follow-up as measured by the BI sum score of the EORTC QLQ-CX24. In contrast, 2 studies, using the FACT-V and BIS questionnaire, did not find any difference in BI between patients treated with ILND and patients treated with SLNB. (Tables 2 and 3 ). Overall, a high incidence of LLL after ILND as compared with a healthy control group was reported (in 2 studies, 68%Y73% vs 11%; P G 0.001). 22, 25 In addition, leg pain and cellulitis were experienced by 53% and 23% of the patients, respectively. 25 In line with these findings, Oonk et al 20 reported that patients who underwent ILND had more discomfort in the groin, vulva, and legs (P = 0.03), resulting in a greater need to wear stockings (P = 0.003), as compared with the SLNB group. Oonk et al 20 used the FACT-V questionnaire supplemented with additional nonvalidated items. Novackova et al 26 observed that LLL after ILND persisted with no signs of improvement at 6-and 12-month follow-up (P = 0.046 and P = 0.028). Moreover, LLL was significantly negatively associated with most of the EORTC QLQ-C30 domains (physical, cognitive, emotional and social function, fatigue, pain, sleep, and financial impact; P G 0.05) indicating worse QoL 22, 25, 26 in addition to lower BI (P = 0.003) 26 and worse SXF. 25 
Urinary Function
Urinary function was assessed in 5 studies 19, 20, 22, 26, 28 by using 4 questionnaires (FACT-V two items and EORTC QLQ-CX24, ePAQ-PF, and ICIQ-SF four items each on urinary function; Tables 2 and 3 ). The FACT-V and the EORTC Self-designed questionnaire CX-24 included urinary items in a common summary score. Novackova et al 26 did not find any difference in Symptom Experience Scale score between patients treated by extensive and those treated with less extensive surgery using the EORTC CX24. Furthermore, no difference was observed at 6-and 12-month follow-up as compared with the baseline level. In line with this, de Melo Ferreira et al 22 did not find any difference in urinary incontinence between VC patients (28 patients) treated with vulvectomy and ILND and healthy controls.
Bowel Function
Assessment of bowel function was included in 6 studies, 19, 20, 22, 24, 26, 28 and 4 questionnaires (EORTC QLQ-C30, EORTC QLQ-CX24, FACT-V, and ePAQ-PF) were used (Tables 2  and 3 ). In the study by Gunther et al, 24 diarrhea was more commonly reported in patients treated with vulvectomy compared with patients treated with WLE. In the study by Novackova et al, 26 patients who received adjuvant RT to the groin in addition to ILND (13 patients) had a higher score on the Symptom Experience Scale from the EORTC CX-24, indicating more symptoms (P = 0.05) at 6 and 12 months, as compared with patients who were not given adjuvant RT (11 patients). It should be noted that reporting on a scale level for the Symptom Experience Scale does not provide any knowledge regarding the origin of symptoms (urinary, bowel, pain, or vulva/vaginal), and individual symptom scores were not reported. 26 
DISCUSSION
To our knowledge, this systematic review is the first to evaluate available PROMs for use in patients with VC. The review was performed to explore the need for development of a VC-specific PROM. Overall, the literature review supports the clinical impression that treatment of VC is associated with long-term consequences within several domains of the patient's well-being. However, the conclusions are vague and probably fail to include symptoms and issues of importance for this particular patient group. The reporting of late effects exhibits great heterogeneity between studies, probably reflecting the lack of a PROM with robust and sensitive scales. Thus, the present study supports the necessity of developing a VC-specific PROM to evaluate disease-and treatment-specific domains in VC patients undergoing different treatment modalities.
Despite wide inclusion criteria, only 11 studies were identified as eligible and most of the studies used PROMs that were generic, were nonYVC-specific, or developed for other cancer diagnoses. We identified only one study that used a VC-specific PROMYFACT-V. 19, 38 The measure has no scale structure but is suggested to be summarized as 1 sum score, although conceptually very different domains are being assessed and the sensitivity of the measured concepts is therefore doubtful.
The psychometric properties have been tested in a comparatively small sample of Australian patients only (20 patients for testretest analyses and additionally 77 patients for the validity analyses, of whom only 8 had received adjuvant radiotherapy). 19, 38 Conceptual scale problems and the fact that reliability and validity have been assessed in only one country in a very limited population preclude broad cross-cultural adaptation. Several areas of potential importance to VC patients were identified. Results for SXF and BI seem to be conflicting. However, the inconsistencies may be attributed to the lack of power due to the small study size and the low percentage of sexually active patients. The well-known reluctance among elderly patients in particular to respond to intimate questions and their minor concern about BI might explain this observation to some point. 20Y22,26 Furthermore, only half of the included studies reported data on partner status. Finally, the instruments for assessment of SXF in VC patients used in the included studies were generally nonvalidated, self-designed, or validated in healthy women or cervical cancer patients. None of the questionnaires assessed potential vulvovaginal problems such as narrowing of the vaginal entrance or swelling of the genital area that may interfere with SXF after VC treatment. The outcomes of the studies in regard to SXF were predominantly sexual activity (yes or no) and an overall female sexual dysfunction total score, which may not properly reflect VC patients' SXF. The present review indicates that despite less extensive and more individualized surgery to the vulva and groin, SXF and BI are likely to deteriorate, especially among patients who have had ILND and/or adjuvant RT. These findings need confirmation in high-quality longitudinal studies including patient-reported vulva-specific outcomes.
Lower limb lymphedema is a disabling complication affecting women with VC after surgery and adjuvant RT of the groin. 40Y42 In the present review, the incidence of LLL in 2 studies was approximately 70%, which was substantially higher than that in the results of previous studies reporting LLL rates between 14% and 48%. 42 It is well known that the incidence of LLL is higher when subjectively assessed using PROMs as compared with using data obtained from medical records. 43 The present review suggests that LLL has a significant negative impact on the QoL after treatment of VC and that LLL may be associated with sexual life disruption, lower physical functioning, and decrease in social activities. 22, 25 The focus in most included studies seemed to be assessment of LLL only. However, retrospective studies not involving PROMs have indicated that lymphedema of the groin and the vulva region also seem to be of great importance for the QoL of VC patients. 11 Therefore, lymphedema of the groin and the vulva should be covered in a future comprehensive assessment of lymphedema in VC patients after treatment.
Less attention has been paid to urinary, bowel, and vulva symptoms after VC treatment. Although these symptoms were assessed in several included studies, the individual scores on urinary, bowel, and vulva symptoms were not provided, but rather included in the Symptom Experience Scale (EORTC CX-24) or in the Vulvar CancerYSpecific Subscale (FACT-V). 20, 26 Several studies on gynecological cancer indicate that severe late effects related to both the small and large intestine, bladder, vagina, and vulva are prevalent after pelvic RT. 13,25,44Y46 Because of small sample sizes in the studies included in the review, the impact of CRT on the VC patient's QoL cannot be validly evaluated.
In conclusion, VC treatment is associated with considerable morbidity and deteriorating QoL. 
